Endomorphins and rubiscolins share a Tyr-Pro start, and both have been tested in the same human neuroblastoma line, SH-SY5Y. This article is for research use only. It describes how published cell studies were designed, not what any compound might do outside a culture dish. If you are new to the wider group, start with our overview of the opioid peptide family. A short editorial in International Journal of Molecular Sciences summarizes the headline finding: neither peptide family was cytotoxic to SH-SY5Y cells, and both were reported to protect the cells against the neurotoxin 6-hydroxydopamine, by different routes (Martini and Tagliazucchi, 2023). Here we look at the design behind that result: the cells, the peptide preparation, the injury models, the readouts and the receptor controls.
Why SH-SY5Y, and which peptides are being compared
SH-SY5Y is a convenient human neuronal-style line that carries its own mu-opioid receptors, so one culture can serve both receptor and stress-response questions.
The cell line
SH-SY5Y cells are human neuroblastoma cells. A 1999 pharmacology study used them precisely because they express mu-opioid receptors endogenously, and compared them with Chinese hamster ovary (CHO) cells engineered to express a recombinant mu receptor (Harrison et al., 1999). In the 2022 neuroprotection work the cells were undifferentiated, grown at 37 °C and 5% CO2 in DMEM:F12 with 10% fetal bovine serum and 1% antibiotic/antimycotic (Perlikowska et al., 2022).
The four peptides
The 2022 study compared four short sequences:
- Endomorphin-1 (EM-1): Tyr-Pro-Trp-Phe-NH2
- Endomorphin-2 (EM-2): Tyr-Pro-Phe-Phe-NH2
- Rubiscolin-5 (R-5): Tyr-Pro-Leu-Asp-Leu
- Rubiscolin-6 (R-6): Tyr-Pro-Leu-Asp-Leu-Phe
All were made by solid-phase synthesis, with purity above 98% confirmed by HPLC and mass spectrometry. Endomorphins are the endogenous pair; the rubiscolins are plant-derived. Two families, one cell line, one injury: that's what makes the comparison useful.
Preparing peptides for cell work
The practical question: is the peptide in the well the one you think it is, at the concentration you think it is?
Identity and purity come first; our guide to reading a certificate of analysis covers what those documents show. Next is the vehicle. In a 2025 endomorphin-analog study, compounds were dissolved in DMSO and the final concentration was kept below 0.1% (v/v), with a matching vehicle control on every plate (Perlikowska et al., 2025). Short peptides are also fragile in biological media. The older binding and cAMP work added a mix of peptidase inhibitors (amastatin, bestatin, captopril and phosphoramidon, each at 30 µM) to limit breakdown during the assay (Harrison et al., 1999). And at low micromolar or nanomolar working concentrations, sticking to labware can matter; see peptide loss to glass and plastic.
Injury models and range-finding
The logic is simple: the cells are first damaged with a known stressor, and the peptide is tested for whether it shifts the readouts back toward untreated cells.
The 6-OHDA design
In the 2022 study, 6-hydroxydopamine (6-OHDA), a neurotoxin used in Parkinson's-style cell models, was applied at 100 µM. Peptide concentrations ranged from 0.1 to 10 µM. Viability, LDH release and BDNF were read after 24 hours; reactive oxygen species (ROS), mitochondrial membrane potential and caspase-3 were read after 6 hours, because those events happen earlier. 6-OHDA alone left viability at 48.63 ± 1.25% of vehicle, a loss of roughly 52%. The peptides were not cytotoxic at 1–10 µM, with one exception: R-6 at 10 µM lowered viability by more than 20% by itself, which is why the peptide-alone arm matters (Perlikowska et al., 2022).